ALK and neoplasm: Using a highly sensitive, commercial CAPP-Seq assay, we demonstrated that ctDNA analyses prior to and early following ALK-TKI treatment initiation may predict clinical outcome and that longitudinal levels of tumor-derived SNVs in the plasma follow clinical response patterns.